1.The glutamate-serine-glycine index as a biomarker to monitor the effects of bariatric surgery on non-alcoholic fatty liver disease
Nichole Yue Ting Tan ; Elizabeth Shumbayawonda ; Lionel Tim-Ee Cheng ; Albert Su Chong Low ; Chin Hong Lim ; Alvin Kim Hock Eng ; Weng Hoong Chan ; Phong Ching Lee ; Mei Fang Tay ; Jason Pik Eu Chang ; Yong Mong Bee ; George Boon Bee Goh ; Jianhong Ching ; Kee Voon Chua ; Sharon Hong Yu Han ; Jean-Paul Kovalik ; Hong Chang Tan
Journal of the ASEAN Federation of Endocrine Societies 2024;39(2):54-60
		                        		
		                        			Objective:
		                        			Bariatric surgery effectively treats non-alcoholic fatty liver disease (NAFLD). The glutamate-serine-glycine (GSG) index has emerged as a non-invasive diagnostic marker for NAFLD, but its ability to monitor treatment response remains unclear. This study investigates the GSG index's ability to monitor NAFLD's response to bariatric surgery.
		                        		
		                        			Methodology:
		                        			Ten NAFLD participants were studied at baseline and 6 months post-bariatric surgery. Blood samples were collected for serum biomarkers and metabolomic profiling. Hepatic steatosis [proton density fat fraction (PDFF)] and fibroinflammation (cT1) were quantified with multiparametric magnetic resonance imaging (mpMRI), and hepatic stiffness with magnetic resonance elastography (MRE). Amino acids and acylcarnitines were measured with mass spectrometry. Statistical analyses included paired Student’s t-test, Wilcoxon-signed rank test, and Pearson’s correlation.
		                        		
		                        			Results:
		                        			Eight participants provided complete data. At baseline, all had hepatic steatosis (BMI 39.3 ± 5.6 kg/m2, PDFF ≥ 5%). Post-surgery reductions in PDFF (from 12.4 ± 6.7% to 6.2 ± 2.8%, p = 0.013) and cT1 (from 823.3 ± 85.4ms to 757.5 ± 41.6ms, p = 0.039) were significant, along with the GSG index (from 0.272 ± 0.03 to 0.157 ± 0.05, p = 0.001).
		                        		
		                        			Conclusion
		                        			The GSG index can potentially be developed as a marker for monitoring the response of patients with NAFLD to bariatric surgery.
		                        		
		                        		
		                        		
		                        			Non-alcoholic Fatty Liver Disease
		                        			;
		                        		
		                        			Amino Acids
		                        			;
		                        		
		                        			Metabolomics
		                        			
		                        		
		                        	
2.Endovascular Management of Hepatic Artery Pseudoaneurysms: A Case Series
Pui Lam CHEUNG ; Yat Sing LEE ; Chong Boon TAN ; Hin Yue LAU ; Chi Wai SIU ; Chik Xing CHAN ; Wai Tat CHAN ; Cheuk Him HO
Vascular Specialist International 2023;39(1):1-
		                        		
		                        			
		                        			 Although rare, hepatic artery aneurysms are associated with a high morbidity and mortality, necessitating a prompt diagnosis. A significant proportion of hepatic artery aneurysms are pseudoaneurysms, and the major risk factors of which have already been identified in previous literatures. Presentation can be variable, but diagnosis almost relies entirely on computed tomography and digital subtraction angiography. The endovascular approach has progressively become the preferred option due to its better performance when compared to the traditional surgical approach. However, formulation of an endovascular treatment plan for these lesions remains difficult as multiple factors should be considered to identify the best endovascular treatment modality. Five cases of pseudoaneurysm due to recent Whipple operation, hepatobiliary infections, and underlying malignancy are presented in this article to illustrate the effectiveness and complexity of endovascular treatment in this disease entity. 
		                        		
		                        		
		                        		
		                        	
3.Clinical efficacy and long-term immunogenicity of an early triple dose regimen of SARS-CoV-2 mRNA vaccination in cancer patients.
Matilda Xinwei LEE ; Siyu PENG ; Ainsley Ryan Yan Bin LEE ; Shi Yin WONG ; Ryan Yong Kiat TAY ; Jiaqi LI ; Areeba TARIQ ; Claire Xin Yi GOH ; Ying Kiat TAN ; Benjamin Kye Jyn TAN ; Chong Boon TEO ; Esther CHAN ; Melissa OOI ; Wee Joo CHNG ; Cheng Ean CHEE ; Carol L F HO ; Robert John WALSH ; Maggie WONG ; Yan SU ; Lezhava ALEXANDER ; Sunil Kumar SETHI ; Shaun Shi Yan TAN ; Yiong Huak CHAN ; Kelvin Bryan TAN ; Soo Chin LEE ; Louis Yi Ann CHAI ; Raghav SUNDAR
Annals of the Academy of Medicine, Singapore 2023;52(1):8-16
		                        		
		                        			INTRODUCTION:
		                        			Three doses of SARS-CoV-2 mRNA vaccines have been recommended for cancer patients to reduce the risk of severe disease. Anti-neoplastic treatment, such as chemotherapy, may affect long-term vaccine immunogenicity.
		                        		
		                        			METHOD:
		                        			Patients with solid or haematological cancer were recruited from 2 hospitals between July 2021 and March 2022. Humoral response was evaluated using GenScript cPASS surrogate virus neutralisation assays. Clinical outcomes were obtained from medical records and national mandatory-reporting databases.
		                        		
		                        			RESULTS:
		                        			A total of 273 patients were recruited, with 40 having haematological malignancies and the rest solid tumours. Among the participants, 204 (74.7%) were receiving active cancer therapy, including 98 (35.9%) undergoing systemic chemotherapy and the rest targeted therapy or immunotherapy. All patients were seronegative at baseline. Seroconversion rates after receiving 1, 2 and 3 doses of SARS-CoV-2 mRNA vaccination were 35.2%, 79.4% and 92.4%, respectively. After 3 doses, patients on active treatment for haematological malignancies had lower antibodies (57.3%±46.2) when compared to patients on immunotherapy (94.1%±9.56, P<0.05) and chemotherapy (92.8%±18.1, P<0.05). SARS-CoV-2 infection was reported in 77 (28.2%) patients, of which 18 were severe. No patient receiving a third dose within 90 days of the second dose experienced severe infection.
		                        		
		                        			CONCLUSION
		                        			This study demonstrates the benefit of early administration of the third dose among cancer patients.
		                        		
		                        		
		                        		
		                        			Humans
		                        			;
		                        		
		                        			SARS-CoV-2
		                        			;
		                        		
		                        			COVID-19/prevention & control*
		                        			;
		                        		
		                        			Treatment Outcome
		                        			;
		                        		
		                        			Neoplasms/drug therapy*
		                        			;
		                        		
		                        			Hematologic Neoplasms
		                        			;
		                        		
		                        			Vaccination
		                        			;
		                        		
		                        			RNA, Messenger
		                        			;
		                        		
		                        			Antibodies, Viral
		                        			;
		                        		
		                        			Immunogenicity, Vaccine
		                        			
		                        		
		                        	
4.A summary of the Malaysian Clinical Practice Guidelines on the management of postmenopausal osteoporosis, 2022
Terence Ing WEI ONG ; Lee Ling LIM ; Siew Pheng CHAN ; Winnie Siew SWEE CHEE ; Alan Swee HOCK CH’NG ; Elizabeth GAR MIT CHONG ; Premitha DAMODARAN ; Fen Lee HEW ; Luqman bin IBRAHIM ; Hui Min KHOR ; Pauline Siew MEI LAI ; Joon Kiong LEE ; Ai Lee LIM ; Boon Ping LIM ; Sharmila Sunita PARAMASIVAM ; Jeyakantha RATNASINGAM ; Yew Siong SIOW ; Alexander Tong BOON TAN ; Nagammai THIAGARAJAN ; Swan Sim YEAP
Osteoporosis and Sarcopenia 2023;9(2):60-69
		                        		
		                        			 Objectives:
		                        			The aim of these Clinical Practice Guidelines is to provide evidence-based recommendations to assist healthcare providers in the screening, diagnosis and management of patients with postmenopausal osteoporosis (OP). 
		                        		
		                        			Methods:
		                        			A list of key clinical questions on the assessment, diagnosis and treatment of OP was formulated. A literature search using the PubMed, Medline, Cochrane Databases of Systematic Reviews, and OVID electronic databases identified all relevant articles on OP based on the key clinical questions, from 2014 onwards, to update from the 2015 edition. The articles were graded using the SIGN50 format. For each statement, studies with the highest level of evidence were used to frame the recommendation. 
		                        		
		                        			Results:
		                        			This article summarizes the diagnostic and treatment pathways for postmenopausal OP. Risk stratification of patients with OP encompasses clinical risk factors, bone mineral density measurements and FRAX risk estimates. Non-pharmacological measures including adequate calcium and vitamin D, regular exercise and falls prevention are recommended. Pharmacological measures depend on patients’ fracture risk status. Very high-risk individuals are recommended for treatment with an anabolic agent, if available, followed by an anti-resorptive agent. Alternatively, parenteral anti-resorptive agents can be used. High-risk individuals should be treated with anti-resorptive agents. In low-risk individuals, menopausal hormone replacement or selective estrogen receptor modulators can be used, if indicated. Patients should be assessed regularly to monitor treatment response and treatment adjusted, as appropriate. 
		                        		
		                        			Conclusions
		                        			The pathways for the management of postmenopausal OP in Malaysia have been updated. Incorporation of fracture risk stratification can guide appropriate treatment. 
		                        		
		                        		
		                        		
		                        	
5.Academy of Medicine, Singapore clinical guideline on the use of sedation by non-anaesthesiologists during gastrointestinal endoscopy in the hospital setting.
Tiing Leong ANG ; Edwin SEET ; Yaw Chong GOH ; Wee Khoon NG ; Calvin Jianyi KOH ; Hock Foong LUI ; James Weiquan LI ; Aung Myint OO ; Kieron Boon Leng LIM ; Kok Sun HO ; Min Hoe CHEW ; Wai Leong QUAN ; Damien Meng Yew TAN ; Kheng Hong NG ; Hak Su GOH ; Wai Kit CHEONG ; Philip TSENG ; Khoon Lin LING
Annals of the Academy of Medicine, Singapore 2022;51(1):24-39
		                        		
		                        			INTRODUCTION:
		                        			In Singapore, non-anaesthesiologists generally administer sedation during gastrointestinal endoscopy. The drugs used for sedation in hospital endoscopy centres now include propofol in addition to benzodiazepines and opiates. The requirements for peri-procedural monitoring and discharge protocols have also evolved. There is a need to develop an evidence-based clinical guideline on the safe and effective use of sedation by non-anaesthesiologists during gastrointestinal endoscopy in the hospital setting.
		                        		
		                        			METHODS:
		                        			The Academy of Medicine, Singapore appointed an expert workgroup comprising 18 gastroenterologists, general surgeons and anaesthesiologists to develop guidelines on the use of sedation during gastrointestinal endoscopy. The workgroup formulated clinical questions related to different aspects of endoscopic sedation, conducted a relevant literature search, adopted Grading of Recommendations, Assessment, Development and Evaluation (GRADE) methodology and developed recommendations by consensus using a modified Delphi process.
		                        		
		                        			RESULTS:
		                        			The workgroup made 16 recommendations encompassing 7 areas: (1) purpose of sedation, benefits and disadvantages of sedation during gastrointestinal endoscopy; (2) pre-procedural assessment, preparation and consent taking for sedation; (3) Efficacy and safety of drugs used in sedation; (4) the role of anaesthesiologist administered sedation during gastrointestinal endoscopy; (5) performance of sedation; (6) post-sedation care and discharge after sedation; and (7) training in sedation for gastrointestinal endoscopy for non-anaesthesiologists.
		                        		
		                        			CONCLUSION
		                        			These recommendations serve to guide clinical practice during sedation for gastrointestinal endoscopy by non-anaesthesiologists in the hospital setting.
		                        		
		                        		
		                        		
		                        			Conscious Sedation
		                        			;
		                        		
		                        			Endoscopy, Gastrointestinal
		                        			;
		                        		
		                        			Hospitals
		                        			;
		                        		
		                        			Humans
		                        			;
		                        		
		                        			Hypnotics and Sedatives
		                        			;
		                        		
		                        			Singapore
		                        			
		                        		
		                        	
6.Return to sport and patient satisfaction after arthroscopic Bankart repair: a single-institution experience.
Yeow Boon TAN ; Ken Lee PUAH ; Roland Weng WAH CHONG ; Kee Leong ONG ; Yi-Jia LIM ; Dave Yee HAN LEE
Singapore medical journal 2022;63(8):433-438
		                        		
		                        			INTRODUCTION:
		                        			Arthroscopic Bankart repair is a widely accepted procedure to treat recurrent shoulder dislocation. This study aims to describe our experience with arthroscopic Bankart repair and its functional outcome.
		                        		
		                        			METHODS:
		                        			107 patients who underwent arthroscopic Bankart repair from 2008 to 2013 were followed up for a minimum of three years and reviewed by an independent observer. 80 consented to being interviewed using the Oxford Shoulder Instability Score (OSIS) and Simple Shoulder Test.
		                        		
		                        			RESULTS:
		                        			82 shoulders (two bilateral) were studied. Mean age at first dislocation was 19.4 ± 3.4 (12.0-31.0) years. Mean follow-up was 4.4 ± 1.3 (3.0-9.0) years and 2.5 ± 3.0 (0.1-15.4) years elapsed from first dislocation to surgery. 41 (50.0%) patients played overhead or contact sports and 44 (53.7%) played competitive sports before injury; 8 (9.8%) patients reported recurrence of dislocation, which was significantly associated with playing competitive sports before injury (p <0.039), 5 (6.1%) underwent revision surgery and 22 (26.8%) reported residual instability after surgery. 49 (59.8%) patients returned to playing sports, 75 (91.5%) were satisfied with their surgery and 79 (96.3%) were willing to undergo the surgery again. 74 (90.2%) patients had two-year good/excellent OSIS, which was significantly associated with playing competitive sports before injury (p = 0.039), self-reported stability after surgery (p = 0.017), satisfaction with surgery (p = 0.018) and willingness to undergo surgery again (p = 0.024).
		                        		
		                        			CONCLUSION
		                        			Arthroscopic Bankart repair yields good functional outcomes and is associated with high patient satisfaction, although not all patients return to sports.
		                        		
		                        		
		                        		
		                        			Humans
		                        			;
		                        		
		                        			Adolescent
		                        			;
		                        		
		                        			Young Adult
		                        			;
		                        		
		                        			Adult
		                        			;
		                        		
		                        			Shoulder Dislocation/complications*
		                        			;
		                        		
		                        			Joint Instability/surgery*
		                        			;
		                        		
		                        			Shoulder Joint/surgery*
		                        			;
		                        		
		                        			Return to Sport
		                        			;
		                        		
		                        			Patient Satisfaction
		                        			;
		                        		
		                        			Retrospective Studies
		                        			;
		                        		
		                        			Recurrence
		                        			;
		                        		
		                        			Arthroscopy/methods*
		                        			
		                        		
		                        	
7.Impact of timely BCR-ABL1 monitoring before allogeneic stem cell transplantation among patients with BCR-ABL1-positive B-acute lymphoblastic leukemia
Siew Lian CHONG ; Asral Wirda AHMAD ASNAWI ; Tze Shin LEONG ; Jenq Tzong TAN ; Kian Boon LAW ; Siong Leng HON ; Rui Jeat FANN ; Sen Mui TAN
Blood Research 2021;56(3):175-183
		                        		
		                        			Background:
		                        			With the emergence of tyrosine kinase inhibitors and the incorporation of stringent measurable residual disease (MRD) monitoring, risk stratification for BCR-ABL1-positive acute lymphoblastic leukemia (ALL) patients has changed significantly. However, whether this monitoring can replace conventional risk factors in determining whether patients need allogeneic stem cell transplantation is still unclear. This study aimed to determine the impact of BCR-ABL1 monitoring on the outcome of patients with BCR-ABL1-positive ALL after allogeneic stem cell transplantation. 
		                        		
		                        			Methods:
		                        			We retrospectively analyzed the survival outcome of patients with BCR-ABL1-positive ALL based on the quantification of BCR-ABL1 at 3 timepoints: the end of induction (timepoint 1), post-consolidation week 16 (timepoint 2), and the end of treatment for patients who were either transplant-eligible or non-transplant eligible (timepoint 3). 
		                        		
		                        			Results:
		                        			From 2006 to 2018, a total of 96 patients newly diagnosed with BCR-ABL1-positive ALL were treated with chemotherapy and tyrosine kinase inhibitors. Thirty-eight (41.3%) patients achieved complete remission, and 33 patients underwent allogeneic stem cell transplantation. Our data showed that pre-transplant MRD monitoring by real-time quantitative polymerase chain reaction had the highest correlation with survival in patients with BCR-ABL1-positive ALL, especially for those who underwent allogeneic stem cell transplantation. 
		                        		
		                        			Conclusion
		                        			Patients without MRD pre-transplantation had superior survival compared with those who had MRD, and they had excellent long-term outcomes after allogeneic stem cell transplantation.
		                        		
		                        		
		                        		
		                        	
8.Impact of timely BCR-ABL1 monitoring before allogeneic stem cell transplantation among patients with BCR-ABL1-positive B-acute lymphoblastic leukemia
Siew Lian CHONG ; Asral Wirda AHMAD ASNAWI ; Tze Shin LEONG ; Jenq Tzong TAN ; Kian Boon LAW ; Siong Leng HON ; Rui Jeat FANN ; Sen Mui TAN
Blood Research 2021;56(3):175-183
		                        		
		                        			Background:
		                        			With the emergence of tyrosine kinase inhibitors and the incorporation of stringent measurable residual disease (MRD) monitoring, risk stratification for BCR-ABL1-positive acute lymphoblastic leukemia (ALL) patients has changed significantly. However, whether this monitoring can replace conventional risk factors in determining whether patients need allogeneic stem cell transplantation is still unclear. This study aimed to determine the impact of BCR-ABL1 monitoring on the outcome of patients with BCR-ABL1-positive ALL after allogeneic stem cell transplantation. 
		                        		
		                        			Methods:
		                        			We retrospectively analyzed the survival outcome of patients with BCR-ABL1-positive ALL based on the quantification of BCR-ABL1 at 3 timepoints: the end of induction (timepoint 1), post-consolidation week 16 (timepoint 2), and the end of treatment for patients who were either transplant-eligible or non-transplant eligible (timepoint 3). 
		                        		
		                        			Results:
		                        			From 2006 to 2018, a total of 96 patients newly diagnosed with BCR-ABL1-positive ALL were treated with chemotherapy and tyrosine kinase inhibitors. Thirty-eight (41.3%) patients achieved complete remission, and 33 patients underwent allogeneic stem cell transplantation. Our data showed that pre-transplant MRD monitoring by real-time quantitative polymerase chain reaction had the highest correlation with survival in patients with BCR-ABL1-positive ALL, especially for those who underwent allogeneic stem cell transplantation. 
		                        		
		                        			Conclusion
		                        			Patients without MRD pre-transplantation had superior survival compared with those who had MRD, and they had excellent long-term outcomes after allogeneic stem cell transplantation.
		                        		
		                        		
		                        		
		                        	
9.Chapter of Gastroenterologists professional guidance for management of patients with liver disease in Singapore during the COVID-19 pandemic.
Jason Pik Eu CHANG ; Yu Jun WONG ; Wei Lyn YANG ; Kieron Boon Leng LIM ; Poh Seng TAN ; Gim Hin HO ; Benjamin Cherng Hann YIP ; James Weiquan LI ; Chern Hao CHONG ; David Eng Hui ONG ; Tju Siang CHUA ; Charles Kien Fong VU ; Kok Ann GWEE ; Tiing Leong ANG ; Chee Kiat TAN
Singapore medical journal 2020;61(12):619-623
		                        		
		                        			
		                        			In this paper, we aim to provide professional guidance to clinicians who are managing patients with chronic liver disease during the current coronavirus disease 2019 (COVID-19) pandemic in Singapore. We reviewed and summarised the available relevant published data on liver disease in COVID-19 and the advisory statements that were issued by major professional bodies, such as the American Association for the Study of Liver Diseases and European Association for the Study of the Liver, contextualising the recommendations to our local situation.
		                        		
		                        		
		                        		
		                        			COVID-19/epidemiology*
		                        			;
		                        		
		                        			Carcinoma, Hepatocellular/therapy*
		                        			;
		                        		
		                        			Chronic Disease
		                        			;
		                        		
		                        			Hepatitis B, Chronic/therapy*
		                        			;
		                        		
		                        			Hepatitis C, Chronic/therapy*
		                        			;
		                        		
		                        			Humans
		                        			;
		                        		
		                        			Liver Cirrhosis/therapy*
		                        			;
		                        		
		                        			Liver Diseases/therapy*
		                        			;
		                        		
		                        			Liver Neoplasms/therapy*
		                        			;
		                        		
		                        			Liver Transplantation
		                        			;
		                        		
		                        			Singapore/epidemiology*
		                        			
		                        		
		                        	
10.Angiosarcoma – a rare fatal cause of recurrent pericardial effusions
Boon Han Ng ; Yi Shan Tan ; Pavitratha Puspanathan ; Chan Tha A Hing ; Nadiah Hanim Zainu ; Chong Hong Lim
The Medical Journal of Malaysia 2020;75(6):759-761
		                        		
		                        			
		                        			A 40-year-old man presented to the Hospital Sultanah
Bahiyah, Alor Setar, Kedah, with constitutional and
respiratory symptoms. Physical examination and
echocardiogram demonstrated massive pericardial effusion.
Patient required multiple attempts of pericardiocentesis due
to recurrent pericardial effusion. Initial workup including
pericardial fluids examination and computed tomography
imaging did not reveal any apparent cause. Magnetic
resonance imaging showed a suspicious mass infiltrating
into the right atrium. Autoimmune screening was negative.
Patient was subsequently treated as having tuberculous
pericarditis. However, his disease progressed rapidly and he
eventually passed away due to right atrial rupture. Postmortem revealed a ruptured right atrial tumour leading to
massive haemothorax. Histopathological examination
confirmed the diagnosis of primary pericardial
angiosarcoma.
		                        		
		                        		
		                        		
		                        	
            

Result Analysis
Print
Save
E-mail